BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 5:04:00 PM | Browse: 1312 | Download: 1184
 |
Received |
|
2013-09-28 15:44 |
|
Peer-Review Started |
|
2013-09-29 12:22 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2013-10-23 11:00 |
|
Revised |
|
2013-10-25 05:29 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-11-13 12:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-11-13 15:17 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-01-20 09:55 |
|
Publish the Manuscript Online |
|
2014-03-12 14:46 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Albert J Czaja |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Albert J Czaja, MD, Professor Emeritus of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN 55905, United States. czaja.albert@mayo.edu |
| Key Words |
Inflammation; Fibrosis; Cirrhosis; Treatment; Anti-oxidants; Angiotensin receptors; Investigational drugs |
| Core Tip |
The prevention of hepatic fibrosis and the reversal of cirrhosis are now achievable objectives in the management of chronic liver disease. Conventional immunosuppressive, anti-inflammatory, and anti-viral therapies can accomplish these outcomes by reducing liver damage, suppressing hepatic inflammation, and eliminating etiological agents, but they do so inconsistently and indirectly. The continuing clarification of pro-fibrotic mechanisms affords opportunities to design site-specific, anti-fibrotic interventions. Anti-oxidants and angiotensin inhibitors have shown promise as adjunctive anti-fibrotic agents in preliminary human studies, and they exemplify a genre of interventions that are likely to influence future management strategies. |
| Publish Date |
2014-03-12 14:46 |
| Citation |
Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i10/2515.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i10.2515 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
